Table 2.
Retrospective comparative studies in adolescents and young adults with acute lymphoblastic leukemia treated with pediatric (P) vs. adult-based (A) protocols.
| Country (reference) | Protocol | Age | N | CR (%) | EFS (%) |
|---|---|---|---|---|---|
| USA (11) | CCG(P) | 16–20 | 197 | 9 | 63 |
| CALGB(A) | 124 | 90 | 34 | ||
| France (12) | FRALLE93(P) | 15–20 | 77 | 94 | 67 |
| LALA94 (A) | 100 | 83 | 41 | ||
| Holland (13) | DCOG (P) | 15–18 | 47 | 98 | 69 |
| HOVON (A) | 44 | 91 | 34 | ||
| Italy (14) | AIEOP (P) | 14–18 | 150 | 94 | 80 |
| GIMEMA (A) | 95 | 89 | 71 | ||
| Sweden (15) | NOPHO-92(P) | 10–40 | 144 | 99 | 65 |
| Adult (A) | 99 | 90 | 48 | ||
| UK (17) | ALL97 (P) | 15–17 | 61 | 98 | 65 |
| UKALLXII(A) | 67 | 94 | 49 | ||
| Mexico (19) | LALIN (P) | 15–25 | 20 | 90 | 70 |
| LALA (A) | 20 | 80 | 40 | ||
| Finland (20) | NOPHO (P) | 10–25 | 128 | 96 | 67 |
| ALL (A) | 97 | 97 | 60 |
N: number of patients; CR: complete remission. EFS: event-free survival